Recent advances in biomarkers and therapeutic interventions for hepatic drug safety – false dawn or new horizon?

References

• Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474–85.
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002 Aug;36(2):451–455.
   PubMed Web of Science ®Google Scholar
• Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005 Apr;61(2):135–143.
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007 Mar;102(3):558–562. quiz 693.
   PubMed Web of Science ®Google Scholar
• Corsini A, Ganey P, Ju C, et al. Current challenges and controversies in drug-induced liver injury. Drug Saf. 2012 Dec 1;35(12):1099–1117.
   PubMed Web of Science ®Google Scholar
• Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015 Aug;63(2):503–14.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010 Jun;51(6):2117–2126.
   PubMed Web of Science ®Google Scholar
• Moggs J, Moulin P, Pognan F, et al. Investigative safety science as a competitive advantage for Pharma. Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1071–1082.
   PubMed Web of Science ®Google Scholar
• Zimmerman HJ. The spectrum of hepatotoxicity. Perspect Biol Med. 1968;12(1):135–161. Autumn
   PubMed Web of Science ®Google Scholar
• Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther. 2011 Jun;89(6):788–790.
   PubMed Web of Science ®Google Scholar
• Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012 Sep;92(3):332–9.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011 Mar 1;34(3):243–252.
   PubMed Web of Science ®Google Scholar
• Merz M, Lee KR, Kullak-Ublick GA, et al. Methodology to assess clinical liver safety data. Drug Saf. 2014 Nov;37(Suppl 1):S33–45.
   PubMed Web of Science ®Google Scholar
• Avigan MI, Bjornsson ES, Pasanen M, et al. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf. 2014 Nov;37(Suppl 1):S19–31.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Merz M, Avigan MI, et al. The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future. Drug Saf. 2014 Nov;37(Suppl 1):S1–7.
   PubMed Web of Science ®Google Scholar
• Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194–205.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994 Apr 6;271(13):992–998.
   PubMed Web of Science ®Google Scholar
• Harrill AH, Roach J, Fier I, et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther. 2012 Aug;92(2):214–220.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• Ratner M. FDA pharmacogenomics guidance sends clear message to industry. Nat Rev Drug Discov. 2005 May;4(5):359.
   PubMed Web of Science ®Google Scholar
• Matheis K, Laurie D, Andriamandroso C, et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today. 2011 Jul;16(13–14):600–608.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Mercer AE, Williams DP, et al. Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica. 2009 Aug;39(8):565–577.
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol. 2010 May;28(5):436–440.
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010 May;28(5):478–485.
   PubMed Web of Science ®Google Scholar
• Urban TJ, Shen Y, Stolz A, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012 Nov;22(11):784–795.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568–579.
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Park BK, Pirmohamed M, et al. Explanation for HLA-B*57:01-linked immune-mediated abacavir-induced hypersensitivity. Pharmacogenomics. 2012 Nov;13(14):1567–1569.
   PubMed Web of Science ®Google Scholar
• Harrill AH, Watkins PB, Su S, et al. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res. 2009 Sep;19(9):1507–1515.
   PubMed Web of Science ®Google Scholar
• Harrill AH, Desmet KD, Wolf KK, et al. A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci. 2012 Dec;130(2):416–426.
   PubMed Web of Science ®Google Scholar
• Starkey Lewis PJ, Merz M, Couttet P, et al. Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther. 2012 Sep;92(3):291–293.
   PubMed Web of Science ®Google Scholar
• Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012 Mar;32(2):326–348.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402–7.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 2010 Dec;56(12):1830–1838.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Dear JW, Starkey LP, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58:777–787 (PMCID: PMC3842113).
   Google Scholar
• Dear JW, Antoine DJ, Starkey-Lewis P, et al. Letter to the Editor: Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis. Br J Clin Pharmacol. 2013 Jul 23. doi:10.1111/bcp.12214.
   Web of Science ®Google Scholar
• Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase (ALT) as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 2014;34:367–378 (PMID: 24118944).
   Google Scholar
• Arrese M, Eguchi A, Feldstein AE. Circulating microRNAs: emerging biomarkers of liver disease. Semin Liver Dis. 2015 Feb;35(1):43–54.
   PubMed Web of Science ®Google Scholar
• Vliegenthart ADB, Starkey LP, Tucker CS, et al. Retro-orbital blood acquisition facilitates circulating microRNA measurement in zebrafish with paracetamol hepatotoxicity. Zebrafish. 2014;11:219–226 (PMCID: PMC4119933).
   Google Scholar
• Sharkey JW, Antoine DJ, Park BK. Validation of the isolation and quantification of kidney enriched miRNAs for use as biomarkers. Biomarkers. 2012 May;17(3):231–239.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195.
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–251.
   PubMed Web of Science ®Google Scholar
• Yang H, Antoine DJ, Andersson U, et al. The many faces of HMGB1: molecular structure-function activity in inflammation, apoptosis and chemotaxis. J Leukoc Biol. 2013;93:865–873 (PMCID: PMC4051189).
   Google Scholar
• Nyström S, Antoine DJ, Lundbäck P, et al. TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO J. 2013 Jan 9;32(1):86–99.
   PubMed Web of Science ®Google Scholar
• Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 2012 Aug 30;488(7413):670–674.
   PubMed Web of Science ®Google Scholar
• Yang H, Lundbäck P, Ottosson L, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med. 2012;18(1):250–259.
   PubMed Web of Science ®Google Scholar
• Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012 Aug 27;209(9):1519–1528.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Harris HE, Andersson U, et al. A systematic nomenclature for the redox states of High Mobility Group Box (HMGB) proteins. Mol Med. 2014;20(1):135–137.
   PubMed Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO Journal. 2003;22(20):5551–5560.
   PubMed Web of Science ®Google Scholar
• Lu B, Antoine DJ, Kwan K, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3068–3073.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Williams DP, Kipar A, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci. 2009 Dec;112(2):521–531.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Williams DP, Kipar A, et al. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med. 2010;16(11–12):479–490.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013 Aug;58(2):777–87.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Jenkins RE, Dear JW, et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol. 2012 May;56(5):1070–9.
   PubMed Web of Science ®Google Scholar
• Huebener P, Pradere JP, Hernandez C, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015 Feb;125(2):539–550.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Ju Z, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015 Jan 12;212(1):5–14.
   PubMed Web of Science ®Google Scholar
• Ge X, Antoine DJ, Lu Y, et al. High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem. 2014 Aug 15;289(33):22672–22691.
   PubMed Web of Science ®Google Scholar
• Woolbright BL, Antoine DJ, Jenkins RE, et al. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):524–531.
   PubMed Web of Science ®Google Scholar
• Stutchfield BM, Antoine DJ, Mackinnon AC, et al. CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology. 2015 Dec;149(7):1896–909 e14.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Kahi C, Francois F, et al. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology. 2002 May;35(5):1282–1284.
   PubMed Web of Science ®Google Scholar
• McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS ONE. 2012;7(8):e43809.
   PubMed Web of Science ®Google Scholar
• Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol. 2014 Oct;25(10):2177–2186.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Sabbisetti VS, Francis B, et al. Circulating kidney injury molecule 1 predicts prognosis and poor outcome in patients with acetaminophen-induced liver injury. Hepatology. 2015 Aug;62(2):591–599.
   PubMed Web of Science ®Google Scholar
• Ku NO, Strnad P, Zhong BH, et al. Keratins let liver live: mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Hepatology. 2007;46(5):1639–1649.
   PubMed Web of Science ®Google Scholar
• Caulín C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol. 1997;138(6):1379–1394.
   PubMed Web of Science ®Google Scholar
• Schutte B, Henfling M, Kölgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res. 2004;297(1):11–26.
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.
   PubMed Web of Science ®Google Scholar
• Cummings J, Hodgkinson C, Odedra R, et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther. 2008;7(3):455–463.
   PubMed Web of Science ®Google Scholar
• Ku NO, Michie SA, Soetikno RM, et al. Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant. J Clin Invest. 1996 Aug 15;98(4):1034–1046.
   PubMed Web of Science ®Google Scholar
• Strnad P, Zhou Q, Hanada S, et al. Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology. 2010 Sep;139(3):828–35, 35 e1–3.
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Jochum C, Kocabayoglu P, et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol. 2010 Oct;53(4):639–647.
   PubMed Web of Science ®Google Scholar
• Feldman BF. Cerebrospinal fluid. In: Kaneko J, editor. Clinical biochemistry of domestic animals. San Diego: Academic Press; 1989. p. 835–865.
   Google Scholar
• Stonard MD. Assessment of nephrotoxicity. In: Evans GO, editor. Animal clinical chemistry. London: Taylor & Francis; 1996. p. 87–89.
   Google Scholar
• Schmidt ES, Schmidt FW. Glutamate dehydrogenase: biochemical and clinical aspects of an interesting enzyme. Clin Chim Acta. 1988 Mar 31;173(1):43–55.
   PubMed Web of Science ®Google Scholar
• Schomaker S, Warner R, Bock J, et al. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci. 2013 Apr;132(2):276–283.
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Slaughter MR, Polley SR, et al. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim. 2002 Jul;36(3):313–321.
   PubMed Web of Science ®Google Scholar
• McGill MR, Sharpe MR, Williams CD, et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest. 2012 Apr 2;122(4):1574–1583.
   PubMed Web of Science ®Google Scholar
• Singhal R, Harrill AH, Menguy-Vacheron F, et al. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol. 2014;15:42. doi:10.1186/2050-6511-15-42.
   Google Scholar
• Jaeschke H, McGill MR. Serum glutamate dehydrogenase–biomarker for liver cell death or mitochondrial dysfunction? Toxicol Sci. 2013 Jul;134(1):221–222.
   PubMed Web of Science ®Google Scholar
• Chen C, Krausz KW, Shah YM, et al. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol. 2009 Apr;22(4):699–707.
   PubMed Web of Science ®Google Scholar
• McGill MR, Li F, Sharpe MR, et al. Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans. Arch Toxicol. 2014 Feb;88(2):391–401.
   PubMed Web of Science ®Google Scholar
• Dear JW, Antoine DJ. Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges. Expert Rev Clin Pharmacol. 2014 Mar;7(2):181–189.
   PubMed Web of Science ®Google Scholar
• Thomas JA, Pope C, Wojtacha D, et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology. 2011 Jun;53(6):2003–2015.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999 Dec 11;319(7224):1541.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Lewis PS, Goldring CE, et al. Are we closer to finding biomarkers for identifying acute drug-induced liver injury? Biomark Med. 2013 Jun;7(3):383–386.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008 Nov;48(5):1680–1689.
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: thinking outside the box. Am Soc Clin Oncol Educ Book. 2015;35:e141–7.
   Google Scholar